Antibody-drug conjugate · developed by Immunome
IM-1617 is an antibody-drug conjugate. It is studied in colorectal cancer, non-small cell lung cancer, breast cancer, esophageal cancer, and stomach cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07578571 | Phase 1 | Colorectal Cancer | Recruiting | IMNM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerCancerColorectal CancerEsophageal CancerNon-Small Cell Lung CancerStomach Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMNM page.
See IMNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMNM catalysts and pipeline →